Schering-Plough

2Q Revenues: $3.2 billion (+13%)

2Q Earnings: $539 million (+108%)

YTD Revenues: $6.2 billion (+15%)

YTD Earnings: $1.1 billion (+75%)

Comments: SP's Remicade sales were up 28% to $394 million. Nasonex sales grew 22% to $295 million. Combined Vytorin/Zetia sales were $1.3 billion (shared with Merck). R&D expenses rose $160 million to $696 million, including a $60 million upfront payment for a licensing deal with Novacea.

News from our sister sites